Samir Parekh, MBBS
-
- Positions
- ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
- ASSOCIATE PROFESSOR | Oncological Sciences
-
- Specialty
- Hematology-Oncology
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
-
- Phone
- Ruttenberg Treatment Center 212-241-7873 212-241-7873
-
Ruttenberg Treatment Center
10 East 102nd Street
6th Floor
New York, NY 10029
Phone: 212-241-7873212-241-7873
Dr. Samir Parekh, MD is an Associate Professor of Medicine (Hematology and Medical Oncology) and Oncological Sciences and Director of Translational Research in Myeloma at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
Dr. Parekh's research focuses on the pathogenesis of hematological malignancies and development of individualized, precision-medicine therapies for these malignancies. His lab uses an integrated systems biology approach to study genome-wide methylation, gene expression and DNA sequence variation to understand pathogenesis, develop biomarkers and guide personalized therapy in B cell malignancies, particularly Multiple Myeloma and Non-Hodgkin's lymphoma.
Dr. Parekh has served on numerous review and advisory committees. He has successfully secured several federal and foundation grants and has authored multiple peer-reviewed publications.
Certification
American Board of Internal Medicine
Clinical Focus
- Lymphoma
- Multiple Myeloma
Research Topics
Computational Biology, Drug Resistance, Epigenetics, Lymphoma, Transcriptional Activation and Repression
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Genetics and Data Science [GDS], Pharmacology and Therapeutics Discovery [PTD]
Education
MBBS, K J Somaiya Medical College
Residency, Internal Medicine
Cook County Hospital
Fellowship, Hematology-Oncology
Montefiore Medical Center /Albert Einstein College of Medicine
Language
English
2005
Young Investigator Award
ASCO
Young Investigator Travel Award
ECOG
First Overall and Highest Rank in General Internal Medicine
K.J. Somaiya Medical College
Mantle Cell Lymphoma (MCL)
MCL is a rare and incurable non-Hodgkins lymphoma whose pathogenesis is not clearly understood. The SOX11 transcription factor is overexpressed in the majority of Mantle cell lymphomas. We identified the direct DNA binding targets of SOX11 in several oncogenic pathways using ChIP-sequencing and functional genomics and have now developed an inducible mouse model of SOX11 overexpression that recapitulates the MCL phenotype. We are developing anti-SOX11 small molecules with structural biologist Dr. Aneel Aggarwal at Mount Sinai that could be applicable in MCL and other SOX11 expressing tumors like lung cancer, ovarian cancer and glioma.
Visit the Parekh Laboratory
Integrative Genomics for Drug repositioning in Myeloma
With the advent of next-generation sequencing, we have been systematically developing and studying the application of integrative genomics (including methylation, gene expression and exome sequencing) to guide personalized repurposing of FDA approved drugs to overcome chemotherapy resistance in B cell malignancies like non-Hodgkins Lymphoma and Multiple Myeloma. I have an ongoing IRB approved clinical trial for genomic signature guided therapeutic selection in collaboration with Drs. Jagannath and Schadt, Dean for Precision Medicine and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Parekh during 2019 and/or 2020. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Foundation Medicine, Inc.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Amgen Inc. / Pfizer Inc. Partnership
- Celgene Corporation
- Karyopharm Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.